DSpace Repository

Antimicrobial drug resistance in Peru

Show simple item record

dc.contributor.author García Apac, Coralith Marlinda
dc.contributor.author Horna, G.
dc.contributor.author Linares, E.
dc.contributor.author Ramírez, R.
dc.contributor.author Tapia, E.
dc.contributor.author Velásquez, J.
dc.contributor.author Medina, V.
dc.contributor.author Guevara, J.
dc.contributor.author Urbina, M.
dc.contributor.author Zevallos, S.
dc.contributor.author Espinoza, N.
dc.contributor.author Samalvides Cuba, Frine
dc.contributor.author Jacobs, J.
dc.date.accessioned 2022-01-18T19:34:44Z
dc.date.available 2022-01-18T19:34:44Z
dc.date.issued 2012
dc.identifier.uri https://hdl.handle.net/20.500.12866/11199
dc.description.abstract To the Editor: In Latin American countries, rates of antimicrobial drug resistance among bacterial pathogens are high. Data on these rates in Peru are incomplete (1), and no institution in Peru has participated in multinational surveillance studies (2–4). To document the antimicrobial drug resistance profile of key pathogens, we organized a surveillance network of clinical laboratories from 9 hospitals (public, general, tertiary care, and quaternary care) in Lima, the capital of Peru. Over a 12-month period (April 2008–March 2009), we consecutively collected positive bacterial blood culture isolates (other than coagulase-negative staphylococci) from each of the 9 hospitals. Only the first isolate per patient was included. Patients’ age and hospital ward were recorded. Identification and susceptibility testing were performed at the Institute of Tropical Medicine Alexander von Humboldt (Lima, Peru)... en_US
dc.language.iso eng
dc.publisher Centers for Disease Control and Prevention
dc.relation.ispartofseries Emerging Infectious Diseases
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Humans en_US
dc.subject Peru en_US
dc.subject controlled study en_US
dc.subject Bacteria en_US
dc.subject letter en_US
dc.subject Anti-Bacterial Agents en_US
dc.subject amikacin en_US
dc.subject bacterium identification en_US
dc.subject meropenem en_US
dc.subject vancomycin en_US
dc.subject Bacterial Infections en_US
dc.subject Escherichia coli en_US
dc.subject bacterium isolate en_US
dc.subject Microbial Sensitivity Tests en_US
dc.subject ciprofloxacin en_US
dc.subject gentamicin en_US
dc.subject antibiotic sensitivity en_US
dc.subject ceftazidime en_US
dc.subject cotrimoxazole en_US
dc.subject antibiotic resistance en_US
dc.subject clindamycin en_US
dc.subject Klebsiella pneumoniae en_US
dc.subject linezolid en_US
dc.subject Drug Resistance, Bacterial en_US
dc.subject piperacillin plus tazobactam en_US
dc.subject teicoplanin en_US
dc.subject erythromycin en_US
dc.subject disk diffusion en_US
dc.subject imipenem en_US
dc.subject Klebsiella pneumoniae infection en_US
dc.subject meticillin en_US
dc.subject Pseudomonas aeruginosa en_US
dc.subject Sentinel Surveillance en_US
dc.subject Staphylococcus aureus en_US
dc.title Antimicrobial drug resistance in Peru en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.3201/eid1803.100878
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.03.08
dc.relation.issn 1080-6059


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/restrictedAccess

Search DSpace


Browse

My Account

Statistics